Recombinant erythropoietin improves cognitive function in chronic haemodialysis patients.
Psychometric performance was studied on two occasions in 18 chronic haemodialysis patients. Nine patients treated with rHuEpo performed a battery of psychometric tests before treatment, haemoglobin [mean (SD)] 5.8 (0.6) g/dl and after partial correction of anaemia, haemoglobin 9.3 (1.28) g/dl. The same battery of psychometric tests was administered on two occasions to nine patients (haemoglobin 7.3 (1.2) g/dl) matched with the treatment group for age, educational status and social class, who did not receive rHuEpo. In the rHuEpo-treated group, IQ, measured by the Wechsler Adult Intelligence Scale-Revised, improved by a mean of 8.7 points (P less than 0.01), while in the control group an improvement by a mean of 2.5 points was not significant. Comparison between the groups of the change in IQ score was significant (P = 0.04). There was no change in the mean scores obtained in either group for the other psychometric tests administered including the Paced Auditory Serial Addition Test, Rey auditory verbal learning, and Borkowski verbal fluency test. These results indicate that anaemia makes a reversible contribution to uraemic cognitive dysfunction.
Temple
R M
RM
Clinical Pharmacology Unit, Royal Infirmary of Edinburgh, UK.
Langan
S J
SJ
Deary
I J
IJ
Winney
R J
RJ
D000328:Adult; D000368:Aged; D000740:Anemia / Q000209:etiology / Q000628:therapy; D003071:Cognition / Q000187:drug effects*; D004921:Erythropoietin / Q000494:pharmacology*; D005260:Female; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007360:Intelligence; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000494:pharmacology; D006435:Renal Dialysis / Q000009:adverse effects
D006454:Hemoglobins; D011994:Recombinant Proteins; D004921:Erythropoietin